PSP Briefing — Cosentyx

Week ending 23 August 2026

1. Self-management questions this week

• Injection/administration technique — 1 direct question (7 responses): Patients asked, “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?” Answers generally directed patients to the device-specific Instructions for Use (IFU), but provided varying levels of practical detail.
• Dosing schedule — 2 direct questions (14 responses): Patients asked, “For Cosentyx dosing in plaque psoriasis, what loading regimen and maintenance dose should I follow?” and “What does Cosentyx’s dosing schedule look like compared with other biologic injections?” Dosing content rose to 20 mentions, up from 17 last week.
• Missed doses, storage/handling, and side-effect self-management: No literal questions this week specifically asked what to do after a missed dose, how to store medication after a temperature excursion, or how to cope with a side effect. Side effects appeared mainly in comparison questions, such as differences between Cosentyx and Humira—not as day-to-day support requests.

2. Where guidance is inconsistent or thin

The clearest practical gap is dosing precision. Responses to the plaque-psoriasis dosing question varied between:

• five weekly loading doses at Weeks 0–4 versus four doses at Weeks 0–3;
• maintenance beginning after Week 4, Week 5, or Week 8.

Because a patient could act on the first schedule they see, PSP materials should provide one simple, indication- and prescription-specific schedule and direct patients to confirm their personal regimen before dosing.

Administration answers consistently said to follow the IFU, but the amount of usable technique guidance varied. The cross-response flags also show inconsistent inclusion of allergic-reaction and infection precautions in administration answers. The high overall hedging rate (120 mentions across 140 responses) suggests patients are often told to “tell me” or consult a clinician without a clear next step. This is particularly relevant when patients are preparing to inject or are unsure whether to proceed.

3. Support-pathway visibility

Answers commonly point patients to the prescriber, pharmacist, or product IFU, but none visibly connect patients to a nurse educator, injection-training service, or PSP hotline. That leaves a structural opportunity: onboarding should clearly explain who to contact for injection technique, dose-calendar questions, missed doses, storage concerns, or side effects, rather than leaving patients to resolve these questions through AI or general pharmacy advice.

4. Trend across weeks

Self-management-related dosing content is building modestly: dosing-specific mentions increased from 17 to 20 this week and have generally risen from 5 on 2 August. Overall question volume remains steady at 20 distinct questions, while inconsistency flags increased from 24 to 26. This supports prioritizing practical content updates rather than treating the issue as a one-off.

5. Recommended actions

1. Urgently validate and standardize the plaque-psoriasis dosing calendar in onboarding, injection training, and hotline scripts, addressing the four-/five-dose and Week 4/5/8 discrepancies.
2. Refresh injection-training materials with device-specific pen/syringe steps, refrigeration and room-temperature handling, and clear “pause and contact support” prompts.
3. Add PSP contact pathways prominently to onboarding, calendar tools, and IFU companion materials.
4. Monitor next week for missed-dose, storage, and side-effect questions; no separate update is indicated yet because none appeared literally this week.